PATIENT WITH CHRONIC HEART FAILURE. RATIONAL CHOICE OF THERAPY
https://doi.org/10.20996/1819-6446-2017-13-4-482-488
Abstract
The theory of chronic hyperactivation of neurohormonal systems, in particular, sympathoadrenal and renin-angiotensin-aldosterone, is the basis of modern concepts of the pathogenesis of heart failure. The medicinal blocking of these two systems has proved to be effective in the treatment of heart failure with reduced ejection fraction (<40%). Antagonists of mineralocorticoid receptors, along with angiotensin-converting enzyme inhibitors and beta-blockers, are neurohumoral modulators. They are used to treat patients with heart failure with reduced ejection fraction. The prescription of mineralocorticoid receptor antagonists in clinical practice remains insufficient despite their high efficacy. Demonstration of the site of mineralocorticoid receptor antagonists in the complex treatment of a patient with chronic heart failure and diabetes type 2 is the goal of this article.
About the Authors
O. M. Drapkina
National Medical Research Center for Preventive Medicine
Russian Federation
Russian Federation
MD, PhD, Professor, Corresponding Member of the Russian Academy of Sciences, Acting Director,
Petroverigsky per. 10-3, Moscow, 101990
D. U. Akasheva
National Medical Research Center for Preventive Medicine
Russian Federation
Russian Federation
MD, PhD, Leading Researcher, Department of Fundamental and Applied Aspects of Obesity,
Petroverigsky per. 10-3, Moscow, 101990
References
1. Weber K.T. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689-97.
2. Maron B.A., Leopold J.A. Aldosterone receptor antagonists: effective but often forgotten. Circulation. 2010;121:934-9
3. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-17
4. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21.
5. Zannad F., McMurray J.J.V., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21
6. Curtis L.H., Mi X., Qualls L.G., et al. Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. Am Heart J. 2013;165:979-86.
7. Dev S.,Hoffman T.K., KavalieratosD., et al. Barriers toAdoption of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure: A Mixed-Methods Study. Am Heart Assoc. 2016;5:e002493
8. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure/The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(27):2129-200
9. Arfe A., Scotti L., Varas-Lorenzo C., et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016;354:i4857.
10. Pitt B., White H., Nicolau J., et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46(3):425-31.
11. Pitt B., Gheorghiade M., Zannad F., et al. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30 %. Eur J Heart Fail. 2006;8(3):295-301.
12. Zannad F., McMurray J.J., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21.
13. Swedberg K., Zannad F., McMurray J.J., et al. Eplerenone and atrial fibrillation in mild systolic heart failure:results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol. 2012;59(18):1598-603.
14. Eschalier R., McMurray J.J.V., Swedberg K., et al. Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function Analyses of the EMPHASIS-HF Study Subgroups (Eplerenone in Mild PatientsHospitalization And SurvIval Study inHeart Failure).J Am Coll Cardiol. 2013;62:1585-93.
15. Rossignol P., Dobre D., McMurray J.J.V., et al. Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy Results From the Eplerenone in Mild PatientsHospitalization and Survival Study inHeart Failure (EMPHASISHF). Circ Heart Fail. 2014;7:51-8.
16. Davies J.I., Band M., Morris A., Struthers A.D. Spironolactone impairs endothelial function and heart rate variability in patients with Type 2 diabetes. Diabetologia. 2004;47:1687-94.
17. Yamaji M., Tsutamoto T., Kawahara C., et al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1(с) levels in patients with chronic heart failure. Am Heart J. 2010;160:915-21.
18. Pitt B., Zannad F. Eplerenone: is it time to add this drug to current heartfailure therapy? TherAdv Chronic Dis. 2012;3(1):5-9.
19. 2016 ESC Guidelines forthe diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur J Heart Fail. 2016;18(8):891-975
Review
For citations:
Drapkina O.M., Akasheva D.U. PATIENT WITH CHRONIC HEART FAILURE. RATIONAL CHOICE OF THERAPY. Rational Pharmacotherapy in Cardiology. 2017;13(4):482-488. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-4-482-488
Views:
743
.jpg)
Email this article 